Peripheral neuropathies and anti-glycolipid antibodies

Brain

Volumn 125, Issue 12, 2002, Pages 2591-2625

  Willison, Hugh J ^a   Yuki, Nobuhiro ^b  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Autoantibody; Autoimmunity; Gangliosides; Guillain Barr syndrome; Peripheral neuropathy

Indexed keywords

GALACTOSYLCERAMIDE; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GD2 ANTIBODY; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GANGLIOSIDE GM3; GANGLIOSIDE GT 1B; GLYCOSPHINGOLIPID; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY TITER; AUTOIMMUNITY; BACTERIAL INFECTION; BACTERIUM ISOLATION; CAMPYLOBACTER JEJUNI; CARBOHYDRATE ANALYSIS; CYTOMEGALOVIRUS INFECTION; ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOMODULATION; INAPPROPRIATE VASOPRESSIN SECRETION; LIMB ISCHEMIA; MEASUREMENT; MELANOMA; MUSCLE WEAKNESS; MYCOPLASMA PNEUMONIAE; NERVE BLOCK; NERVE ENDING; NEUROMUSCULAR SYNAPSE; NONHUMAN; OPHTHALMOPLEGIA; PARAPROTEINEMIA; PASSIVE IMMUNIZATION; PHENOTYPE; POLYNEUROPATHY; PRIORITY JOURNAL; RANVIER NODE; REVIEW; SPINAL GANGLION;

EID: 0036895610     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awf272     Document Type: Review

References (284)

1. Adams D, Kuntzer T, Burger D, Chofflon M, Magistris MR, Regli F, et al. Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: A study of 180 sera. J Neuroimmunol 1991; 32: 223-30.
2. Al-Din AN, Anderson M, Bickerstaff ER, Harvey I. Brainstem encephalitis and the syndrome of Miller Fisher: A clinical study. Brain 1982; 105: 481-95.
3. Al-Din AS, Jamil AS, Shakir R. Coma and brain stem areflexia in brain stem encephalitis (Fisher's syndrome) [letter]. Br Med J 1985; 291: 535-6.
4. Allos BM. Association between Campylobacter infection and Guillain-Barré syndrome. [Review]. J Infect Dis 1997; 176 Suppl 2: S125-8.
5. Ang CW, Yuki N, Jacobs BC, Koga M, Van Doorn PA, Schmitz PI, et al. Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies. Neurology 1999; 53: 2122-7.
6. Ang CW, Endtz HP, Jacobs BC, Laman JD, de Klerk MA, van der Meché FG, et al. Campylobacter jejuni lipopolysaccharides from Guillain-Barré syndrome patients induce IgG anti-GM1 antibodies in rabbits. J Neuroimmunol 2000a; 104: 133-8.
7. Ang CW, Jacobs BC, Brandenburg AH, Laman JD, van der Meché FG, Osterhaus AD, et al. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome. Neurology 2000b; 54: 1453-8.
8. Arai M, Yoshino H, Kusano Y, Yazaki Y, Ohnishi Y, Miyatake T. Ataxic polyneuropathy and anti-Pr2 IgMkappa M proteinemia. J Neurol 1992; 239: 147-51.
9. Arasaki K, Kusunoki S, Kudo N, Kanazawa I. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve 1993; 16: 587-93.
10. Ariga T, Kohriyama T, Freddo L, Latov N, Saito M, Kon K, et al. Characterization of sulfated glucuronic acid containing glycolipids reacting with IgM M-proteins in patients with neuropathy. J Biol Chem 1987; 262: 848-53.
11. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis: Its role in pathogenesis. Medicine (Baltimore) 1969; 48: 173-215.
12. Aspinall GO, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharides of Campylobacter jejuni serotype O:19: Structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 1994; 33: 241-9.
13. Bansal AS, Abdul-Karim B, Malik RA, Goulding P, Pumphrey RS, Boulton AJ, et al. IgM ganglioside GM1 antibodies in patients with autoimmune disease or neuropathy, and controls. J Clin Pathol 1994; 47: 300-2.
14. Bech E, Jakobsen J, Orntoft TF. ELISA-type titertray assay of IgM anti-GM1 autoantibodies. Clin Chem 1994; 40: 1331-4.
15. Ben Younes-Chennoufi A, Meininger V, Leger JM, Bouche P, Jauberteau MO, Baumann N. Antiganglioside antibodies in motorneuron diseases and peripheral neuropathies: Study by ELISA technique and immunodetection on thin-layer chromatography. Neurochem Int 1992; 20: 353-7.
16. Bickerstaff ER. Brain-stem encephalitis: Further observations on a grave syndrome with benign prognosis. Br Med J 1957; 1: 1384-7.
17. Bickerstaff ER, Cloake PCP. Mesencephalitis and rhombencephalitis. Br Med J 1951; 2: 77-81.
18. o in serum from patients with monoclonal IgM gammopathy and polyneuropathy. Neurology 1988; 38: 1266-70.
19. Braun PE, Frail DE, Latov N. Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem 1982; 39: 1261-5.
20. Buchwald B, Weishaupt A, Toyka KV, Dudel J. Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice. Neurosci Lett 1995; 201: 163-6.
21. Buchwald B, Weishaupt A, Toyka KV, Dudel J. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 1998; 10: 281-90.
22. Carpo M, Nobile-Orazio E, Meucci N, Gamba M, Barbieri S, Allaria S, et al. Anti-GD1a ganglioside antibodies in peripheral motor syndromes. Ann Neurol 1996; 39: 539-43.
23. Carpo M, Pedotti R, Lolli F, Pitrola A, Allaria S, Scarlato G, et al. Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy. J Neurol Sci 1998; 155: 186-91.
24. Chassande B, Leger JM, Younes-Chennoufi AB, Bengoufa D, Maisonobe T, Bouche P, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: Correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 1998; 21: 55-62.
25. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992; 31: 677-9.
26. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: Clinical and immunohistochemical studies. Neurology 1993; 43: 1911-7.
27. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with specific reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997; 745: 32-6.
28. Chou DK, Ilyas AA, Evans JE, Costello C, Quarles RH, Jungalwala FB. Structure of sulfated glucuronyl glycolipids in the nervous system reacting with HNK-1 antibody and some IgM paraproteins in neuropathy. J Biol Chem 1986; 261: 11717-25.
29. Corbo M, Quattrini A, Lugaresi A, Santoro M, Latov N, Hays AP. Patterns of reactivity of human anti-GM1 antibodies with spinal cord and motor neurons. Ann Neurol 1992; 32: 487-93.
30. Corbo M, Quattrini A, Latov N, Hays AP. Localization of GM1 and Gal(beta1-3)GalNAc antigenic determinants in peripheral nerve. Neurology 1993; 43: 809-14.
31. Daune GC, Farrer RG, Dalakas MC, Quarles RH. Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside. Ann Neurol 1992; 31: 683-5.
32. Derrington EA, Borroni E. The developmental expression of the cholinergic-specific antigen Chol-1 in the central and peripheral nervous system of the rat. Brain Res Dev Brain Res 1990; 52: 131-40.
33. Dodd J, Jessell TM. Lactoseries carbohydrates specify subsets of dorsal root ganglion neurons projecting to the superficial dorsal horn of rat spinal cord. J Neurosci 1985; 5: 3278-94.
34. Dodd J, Solter D, Jessell TM. Monoclonal antibodies against carbohydrate differentiation antigens identify subsets of primary sensory neurones. Nature 1984; 311: 469-72.
35. Duchen LW, Gomez S, Queiroz LS. The neuromuscular junction of the mouse after black widow spider venom. J Physiol 1981; 316: 279-91.
36. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Guillain-Barré syndrome variants in Emilia-Romagna, Italy, 1992-3: Incidence, clinical features, and prognosis. J Neurol Neurosurg Psychiatry 1998; 65: 218-24.
37. Enders U, Karch H, Toyka KV, Michels M, Zielasek J, Pette M, et al. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol 1993; 34: 136-44.
38. Fagarasan S, Honjo T. T-independent immune response: New aspects of B cell biology. Science 2000; 290: 89-92.
39. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AD, Koopman WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986; 109: 1115-26.
40. Figueras A, Morales-Olivas FJ, Capellà D, Palop V, Laporte J-R. Bovine gangliosides and acute motor polyneuropathy. Br Med J 1992; 305: 1330-1.
41. Fisher M. An unusual variant of acute idiopathic polyneuritis: Syndrome of ophthalmoplegia, ataxia and areflexia. N Engl J Med 1956; 255: 57-65.
42. Freddo L, Yu RK, Latov N, Donofrio PD, Hays AP, Greenberg HS, et al. Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology 1986; 36: 454-8.
43. Fredman P, Vedeler CA, Nyland H, Aarli JA, Svennerholm L. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulfatide of peripheral nerve myelin. J Neurol 1991; 238: 75-9.
44. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids. Ann Neurol 1987; 22: 753-61.
45. Gabriel CM, Gregson NA, Hughes RA. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol 2000; 104: 139-46.
46. Ganser AL, Kirschner DA. Differential expression of gangliosides on the surfaces of myelinated nerve fibers. J Neurosci Res 1984; 12: 245-55.
47. Ganser AL, Kirschner DA, Willinger M. Ganglioside localization on myelinated nerve fibres by cholera toxin binding. J Neurocytol 1983; 12: 921-38.
48. Garcia Guijo C, Garcia Merino A, Rubio G, Guerrero A, Cruz Martinez A, Arpa J. IgG anti-ganglioside antibodies and their subclass distribution in two patients with acute and chronic motor neuropathy. J Neuroimmunol 1992; 37: 141-8.
49. Gong Y, Lunn MP, Heffer-Lauc M, Li CY, Griffin JW, Schnaar RL, et al. Localization of major gangliosides in the PNS: Implications for immune neuropathies [abstract]. J Periph Nerv Syst 2001; 6: 142.
50. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, et al. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999; 104: 697-708.
51. Govoni V, Granieri E, Tola MR, Paolino E, Casetta I, Fainardi E, et al. Exogenous gangliosides and Guillain-Barré syndrome: An observational study in the local health district of Ferrara, Italy. Brain 1997; 120: 1123-30.
52. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996a; 39: 17-28.
53. Griffin JW, Li CY, Macko C, Ho TW, Hsieh S-T, Xue P, et al. Early nodal change in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 1996b; 25: 33-51.
54. Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096-104.
55. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire: Remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bull Soc Med Hop Paris 1916; 40: 1462-70.
56. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome. Ann Neurol 1998; 44: 780-8.
57. Hafer-Macko C, Hsieh S-T, Li CY, Ho TW, Sheikh K, Cornblath DR, et al. Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann Neurol 1996a; 40: 635-44.
58. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996b; 39: 625-35.
59. Hao Q, Saida T, Kuroki S, Nishimura M, Nukina M, Obayashi H, et al. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. J Neuroimmunol 1998; 81: 116-26.
60. Hao Q, Saida T, Yoshino H, Kuroki S, Nukina M, Saida K. Anti-GalNAc-GD1a antibody-associated Guillain-Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann Neurol 1999; 45: 758-68.
61. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome. Part 1. [Review]. Muscle Nerve 1995a; 18: 137-53.
62. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome. Part 2. [Review]. Muscle Nerve 1995b; 18: 154-64.
63. Harvey GK, Toyka KV, Zielasek J, Kiefer R, Simonis C, Hartung HP. Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve 1995; 18: 388-94.
64. Hays AP, Latov N, Takatsu M, Sherman WH. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology 1987; 37: 242-56.
65. 1d specificity in a patient with peripheral neuropathy. Vox Sang 1994; 67: 58-63.
66. Hirabayashi Y, Nakao T, Matsumoto M, Obata K, Ando S. Improved method for large-scale purification of brain gangliosides by Q-sepharose column chromatography: Immunochemical detection of C-series polysialogangliosides in adult bovine brains. J Chromatogr 1988; 445: 377-84.
67. Hirakawa M, McCabe T, Kawata M. Time-related changes in the labeling pattern of motor and sensory neurons innervating the gastrocnemius muscle, as revealed by the retrograde transport of the cholera toxin B subunit. Cell Tissue Res 1992; 267: 419-27.
68. Hirota N, Kaji R, Bostock H, Shindo K, Kawasaki T, Mizutani K, et al. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain 1997; 120: 2159-69.
69. Hitoshi S, Kusunoki S, Murayama S, Tsuji S, Kanazawa I. Rabbit experimental sensory ataxic neuropathy: Anti-GD1b antibody-mediated trkC downregulation of dorsal root ganglia neurons. Neurosci Lett 1999; 260: 157-60.
70. Ho TW, Hsieh S-T, Nachamkin I, Willison HJ, Sheikh K, Kiehlbauch J, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997; 48: 717-24.
71. Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999; 45: 168-73.
72. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. [Review]. J Infect Dis 1997; 176 Suppl: S92-8.
73. Hughes R, Atkinson P, Coates P, Hall S, Leibowitz S. Sural nerve biopsies in Guillain-Barre syndrome: Axonal degeneration and macrophage-associated demyelination and absence of cytomegalovirus genome. Muscle Nerve 1992; 15: 568-75.
74. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barre syndrome. [Review]. J Neuroimmunol 1999; 100: 74-97.
75. Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 1995; 38: 218-24.
76. Ilyas AA, Quarles RH, Dalakas MC, Fishman PH, Brady RO. Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Ann Neurol 1985; 18: 655-9.
77. Ilyas AA, Willison HJ, Dalakas MC, Whitaker JN, Quarles RH. Identification and characterization of gangliosides reacting with IgM paraproteins in three patients with neuropathy associated with biclonal gammopathy. J Neurochem 1988a; 51: 851-8.
78. Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, et al. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 1988b; 23: 440-7.
79. Ilyas AA, Li S-C, Chou DK, Li Y-T, Jungalwala FB, Dalakas MC, et al. Gangliosides GM2, IV4GalNAcGM1b, and IV4GalNAcGD1a as antigens for monoclonal immunoglobulin M in neuropathy associated with gammopathy. J Biol Chem 1988c; 263: 4369-73.
80. Ilyas AA, Mithen FA, Chen Z-W, Cook SD. Search for antibodies to neutral glycolipids in sera of patients with Guillain-Barré syndrome. J Neurol Sci 1991; 102: 67-75.
81. Ilyas AA, Mithen FA, Dalakas MC, Chen Z-W, Cook SD. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1992; 107: 111-21.
82. Inuzuka T, Miyatani N, Baba H, Tanaka M, Tanaka K, Sato S, et al. IgM binding to sialosyllactosaminylparagloboside in a patient with polyradiculoneuropathy due to Mycoplasma pneumoniae infection. Acta Neurol Scand 1988; 78: 53-7.
83. Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukazawa T, et al. Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol 1996; 68: 19-26.
84. Irie S, Kanazawa N, Ogino M, Saito T, Funato T. No cytomegalovirus DNA in sera from patients with anti-MAG/SGPG antibody-associated neuropathy [letter]. Ann Neurol 2000; 47: 274.
85. IUPAC-IUB Commission on Biochemical Nomenclature (CBN). The nomenclature of lipids. Eur J Biochem 1977; 79: 11-21.
86. Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996; 40: 181-7.
87. Jacobs BC, Hazenberg MP, van Doorn PA, Endtz HP, van der Meché FG. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J Infect Dis 1997a; 175: 729-33.
88. Jacobs BC, Meulstee J, van Doorn PA, van der Meché FG. Electrodiagnostic findings related to anti-GMI and anti-GQ1b antibodies in Guillain-Barré syndrome. Muscle Nerve 1997b; 20: 446-52.
89. Jacobs BC, van Doorn PA, Groeneveld JH, Tio-Gillen AP, van der Meché FG. Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997c; 62: 641-3.
90. Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, Schmitz PI, de Klerk MA, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: A case-control study. Neurology 1998; 51: 1110-5.
91. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. Guillain-Barré syndrome with antibody to a ganglioside, N-acetylgalactosaminyl GD1a. Brain 2000; 123: 116-24.
92. Kaldor J, Speed BR. Guillain-Barré syndrome and Campylobacter jejuni: A serological study. Br Med J 1984; 288: 1867-70.
93. Kanda T, Yoshino H, Ariga T, Yamawaki M, Yu RK. Glycosphingolipid antigens in cultured bovine brain microvascular endothelial cells: Sulfoglucuronosyl paragloboside as a target of monoclonal IgM in demyelinative neuropathy [corrected]. J Cell Biol 1994; 126: 235-46.
94. Kashihara K, Shiro Y, Koga M, Yuki N. IgG anti-GT1a antibodies which do not cross react with GQlb ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome [letter]. J Neurol Neurosurg Psychiatry 1998; 65: 799.
95. Khalili-Shirazi A, Gregson N, Gray I, Rees J, Winer J, Hughes R. Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry 1999; 66: 376-9.
96. Kitazawa K, Tagawa Y, Honda A, Yuki N. Guillain-Barré syndrome associated with IgG anti-GM1b antibody subsequent to Mycoplasma pneumoniae infection. J Neurol Sci 1998; 156: 99-101.
97. Koga M, Yuki N, Ariga T, Morimatsu M, Hirata K. Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome? J Neuroimmunol 1998a; 86: 74-9.
98. Koga M, Yuki N, Takahashi M, Saito K, Hirata K. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barré and Fisher's syndromes. J Neuroimmunol 1998b; 81: 138-43.
99. Koga M, Yuki N, Ariga T, Hirata K. Antibodies to GD3, GT3, and O-acetylated species in Guillain-Barré and Fisher's syndromes: Their association with cranial nerve dysfunction. J Neurol Sci 1999a; 164: 50-5.
100. Koga M, Yuki N, Hirata K. Antiganglioside antibody in patients with Guillain-Barré syndrome who show bulbar palsy as an initial symptom. J Neurol Neurosurg Psychiatry 1999b; 66: 513-6.
101. Koga M, Yuki N, Tai T, Hirata K. Miller Fisher syndrome and Haemophilus influenzae infection. Neurology 2001; 57: 686-91.
102. Koga M, Yoshino H, Morimatsu M, Yuki N. Anti-GT1a IgG in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2002; 72: 767-71.
103. Kohriyama T, Ariga T, Yu RK. Preparation and characterization of antibodies against a sulfated glucuronic acid-containing glycosphingolipid. J Neurochem 1988; 51: 869-77.
104. Kornberg AJ, Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing. [Review]. Muscle Nerve 1994; 17: 100-4.
105. Kornberg AJ, Pestronk A. Chronic motor neuropathies: diagnosis, therapy, and pathogenesis. [Review]. Ann Neurol 1995; 37 Suppl 1: S43-50.
106. Kornberg AJ, Pestronk A, Bieser K, Ho TW, McKhann GM, Wu HS, et al. The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol 1994; 35: 234-7.
107. Koski CL, Humphrey R, Shin ML. Anti-peripheral myelin antibody in patients with demyelinating neuropathy: Quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci USA 1985; 82: 905-9.
108. Koski CL, Chou DH, Jungalwala FB. Anti-peripheral nerve myelin antibodies in Guillain-Barré syndrome bind a neutral glycolipid of peripheral nerve myelin and cross-react with Forssman antigen. J Clin Invest 1989; 84: 280-7.
109. Kuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, et al. Campylobacter jejuni strains from patients with Guillain-Barre syndrome belong mostly to Penner serogroup 19 and contain? beta-N-acetylglucosamine residues. Ann Neurol 1993; 33: 243-7.
110. Kusunoki S, Chiba A, Hirabayashi Y, Irie F, Kotani M, Kawashima I, et al. Generation of a monoclonal antibody specific for a new class of minor ganglioside antigens, GQ1b alpha and GT1a alpha: Its binding to dorsal and lateral horn of human thoracic cord. Brain Res 1993a; 623: 83-8.
111. Kusunoki S, Chiba A, Tai T, Kanazawa I. Localization of GM1 and GD1b antigens in the human peripheral nervous system. Muscle Nerve 1993b; 16: 752-6.
112. Kusunoki S, Chiba A, Kon K, Ando S, Arisawa K, Tate A, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol 1994; 35: 570-6.
113. Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 1995; 18; 409-13.
114. Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. GM1b is a new member of antigen for serum antibody in Guillain-Barré syndrome. Neurology 1996a; 47: 237-42.
115. Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 1996b; 39: 424-31.
116. Kusunoki S, Takizawa H, Kanazawa I. Infection by Mycoplasma pneumoniae induces serum antibody against Gal-C [letter]. Muscle Nerve 1996c; 19: 257-8.
117. Kusunoki S, Chiba A, Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 1999a; 22: 1071-4.
118. Kusunoki S, Hitoshi S, Kaida K, Arita M, Kanazawa I. Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. Ann Neurol 1999b; 45: 400-3.
119. Kusunoki S, Hitoshi S, Kaida K, Murayama S, Kanazawa I. Degeneration of rabbit sensory neurons induced by passive transfer of anti-GD1b antiserum. Neurosci Lett 1999c; 273: 33-6.
120. Kusunoki S, Shiina M, Kanazawa I. Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection: Evidence of molecular mimicry. Neurology 2001; 57: 736-8.
121. Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T. Two patterns of clinical recovery in Guillain-Barré syndrome with anti-GM1 antibody. Neurology 1998a; 51: 1656-60.
122. Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998b; 44: 202-8.
123. Kuwabara S, Asahina M, Nakajima M, Mori M, Fukutake T, Hattori T, et al. Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Ann Neurol 1999; 45: 533-6.
124. Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M, et al. Intravenous immunoglobulin therapy for Guillain-Barre syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001; 24: 54-8.
125. Kwa MS, van Schaik IN, Brand A, Baas F, Vermeulen M. Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. J Neuroimmunol 2001; 116: 220-5.
126. Kyle RA. Monoclonal proteins in neuropathy. [Review]. Neurol Clin 1992; 10: 713-34.
127. Lafontaine S, Rasminsky M, Saida T, Sumner AJ. Conduction block in rat myelinated fibres following acute exposure to anti-galactocerebroside serum. J Physiol 1982; 323: 287-306.
128. Landi G, D'Alessandro R, Dossi BC, Ricci S, Simone IL, Ciccone A. Guillain-Barré syndrome after exogeneous gangliosides in Italy. Br Med J 1993; 307: 1463-4.
129. Latov N. Antibodies to glycoconjugates in neuropathy and motor-neuron disease. [Review]. Proc Brain Res 1994; 101: 295-303.
130. Latov N, Sherman WH, Nemni R, Galassi G, Shyong JS, Penn AS, et al. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. New Engl J Med 1980; 303: 618-21.
131. Latov N, Hays AP, Donofrio PD, Liao J, Ito H, McGinnis S, et al. Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-tetraose associated with human motor neuron disease. Neurology 1988; 38: 763-8.
132. Ledeen R. Gangliosides of the neuron. [Review]. Trends Neurosci 1985; 8: 169-74.
133. Ledeen RW, Yu RK. Gangliosides: Structure, isolation, and analysis. [Review]. Methods Enzymol 1982; 83: 139-91.
134. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study. Brain 2001; 124: 145-53.
135. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999; 52: 1701-4.
136. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32: 958-64.
137. Lloyd KO, Gordon CM, Thampoe IJ, DiBenedetto C. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res 1992; 52: 4948-53.
138. Lopate G, Parks BJ, Goldstein JM, Yee WC, Friesenhahn GM, Pestronk A. Polyneuropathies associated with high titre antisulphatide antibodies: Characteristics of patients with and without serum monoclonal proteins. J Neurol Neurosurg Psychiatry 1997; 62: 581-5.
139. Lunn MP, Muir P, Brown LJ, MacMahon EM, Gregson NA, Hughes RA. Cytomegalovirus is not associated with IgM anti-myelin-associated glycoprotein/sulphate-3-glucuronyl paragloboside antibody-associated neuropathy. Ann Neurol 1999; 46: 267-70.
140. Maeda Y, Bigbee JW, Maeda R, Miyatani N, Kalb RG, Yu RK. Induction of demyelination by intraneural injection of antibodies against sulfoglucuronyl paragloboside. Exp Neurol 1991; 113: 221-5.
141. Maehara T, Ono K, Tsutsui K, Watarai S, Yasuda T, Inoue H, et al. A monoclonal antibody that recognizes ganglioside GD1b in the rat central nervous system. Neurosci Res 1997; 29: 9-16.
142. Marcus DM, Latov N, Hsi BP, Gillard BK. Measurement and significance of antibodies against GM1 ganglioside: Report of a workshop, 18 April 1989, Chicago, IL, USA. J Neuroimmunol 1989; 25: 255-9.
143. Matsumoto A, Yoshino H, Yuki N, Hara Y, Cashman NR, Handa S, et al. Ganglioside characterization of a cell line displaying motor neuron-like phenotype: GM2 as a possible major ganglioside in motor neurons. J Neurol Sci 1995; 131: 111-8.
144. McFarlin DE. Immunological parameters in Guillain-Barré syndrome. [Review]. Ann Neurol 1990; 27 Suppl: S25-29.
145. McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, et al. Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33: 333-42.
146. Miescher GC, Steck AJ. Paraproteinaemic neuropathies. [Review]. Baillieres Clin Neurol 1996; 5: 219-32.
147. Mitsumoto H, Sliman RJ, Schafer IA, Sternick CS, Kaufman B, Wilbourn A, et al. Motor neuron disease and adult hexosaminidase A deficiency in two families: Evidence for multisystem degeneration. Ann Neurol 1985; 17: 378-85.
148. Miyazaki T, Kusunoki S, Kaida K, Shiina M, Kanazawa I. Guillain-Barré syndrome associated with IgG monospecific to ganglioside GD1b. Neurology 2001; 56: 1227-9.
149. Mizoguchi K, Hase A, Obi T, Matsuoka H, Takatsu M, Nishimura Y, et al. Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1994; 57: 1121-3.
150. Molander M, Berthold C-H, Persson H, Andersson K, Fredman P. Monosialoganglioside (GM1) immunofluorescence in rat spinal roots studied with a monoclonal antibody. J Neurocytol 1997; 26: 101-11.
151. Monaco S, Ferrari S, Bonetti B, Moretto G, Kirshfink M, Nardelli E, et al. Experimental induction of myelin changes by anti-MAG antibodies and terminal complement complex. J Neuropathol Exp Neurol 1995; 54: 96-104.
152. Mori M, Kuwabara S, Koga M, Asahina M, Ogawara K, Hattori T, et al. IgG anti-GQ1b positive acute ataxia without ophthalmoplegia. J Neurol Neurosurg Psychiatry 1999a; 67: 668-70.
153. Mori M, Kuwabara S, Miyake M, Dezawa M, Adachi-Usami E, Kuroki H, et al. Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barré syndrome. Neurology 1999b; 52: 1282-4.
154. Mori M, Kuwabara S, Miyake M, Noda M, Kuroki H, Kanno H, et al. Haemophilus influenzae infection and Guillain-Barré syndrome. Brain 2000; 123: 2171-8.
155. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 1989; 49: 2857-61.
156. Nagai Y, Momoi T, Saito M, Mitsuzawa E, Ohtani S. Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides. Neurosci Lett 1976; 2: 107-11.
157. Neisser A, Bernheimer H, Berger T, Moran AP, Schwerer B. Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller Fisher syndrome. Infect Immun 1997; 65: 4038-42.
158. Nishimura M, Saida T, Kuroki S, Kawabata T, Obayashi H, Saida K, et al. Post-infectious encephalitis with anti-galactocerebroside antibody subsequent to Mycoplasma pneumoniae infection. J Neurol Sci 1996; 140: 91-5.
159. Nobile-Orazio E, Manfredini E, Carpo M, Meucci N, Monaco S, Ferrari S, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994; 36: 416-24.
160. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000; 123: 710-7.
161. Obi T, Kusunoki S, Takatsu M, Mizoguchi K, Nishimura Y. IgM M-protein in a patient with sensory-dominant neuropathy binds preferentially to polysialogangliosides. Acta Neurol Scand 1992; 86: 215-8.
162. Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: Clinical and immunological range. J Neurol Neurosurg Psychiatry 2001a; 70: 50-5.
163. Odaka M, Yuki N, Hirata K. Bickerstaff's brainstem encephalitis with and without limb weakness: The relationship [abstract]. J Neurol Sci 2001b; 187 Suppl: S489.
164. Ogawa-Goto K, Abe T. Gangliosides and glycosphingolipids of peripheral nervous system myelins: A minireview. [Review]. Neurochem Res 1998; 23: 305-10.
165. Ogawa-Goto K, Funamoto N, Ohta Y, Abe T, Nagashima K. Myelin gangliosides of human peripheral nervous system: An enrichment of GM1 in the motor nerve myelin isolated from cauda equina. J Neurochem 1992; 59: 1844-9.
166. Ogawa-Goto K, Kubota K, Kurotani A, Abe T. Antibodies against sulfated glycosphingolipids of peripheral nerve myelins detected in patients with human cytomegalovirus infection. J Neuroimmunol 1994; 55: 55-60.
167. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: Relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000; 48: 624-31.
168. O'Hanlon GM, Paterson GJ, Wilson G, Doyle D, McHardie P, Willison HJ. Anti-GM1 ganglioside antibodies cloned from autoimmune neuropathy patients show diverse binding patterns in the rodent nervous system. J Neuropathol Exp Neurol 1996; 55: 184-95.
169. O'Hanlon GM, Paterson GJ, Veitch J, Wilson G, Willison HJ. Mapping immunoreactive epitopes in the human peripheral nervous system using human monoclonal anti-GM1 ganglioside antibodies. Acta Neuropathol (Berl) 1998; 95: 605-16.
170. O'Hanlon GM, Veitch J, Gallardo E, Ilia I, Chancellor AM, Willison HJ. Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: Clinical and immunopathological studies. Autoimmunity 2000; 32: 133-44.
171. O'Hanlon GM, Plomp JJ, Chakrabarti M, Morrison I, Wagner, ER, Goodyear CS, et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 2001; 124: 893-906.
172. Ohsawa T, Miyatake T, Yuki N. Anti-B-series ganglioside-recognizing autoantibodies in an acute sensory neuropathy patient cause cell death of rat dorsal root ganglion neurons. Neurosci Lett 1993; 157: 167-70.
173. Okamoto M, Longenecker HE Jr, Riker WF Jr, Song SK. Destruction of mammalian motor nerve terminals by black widow spider venom. Science 1971; 172: 733-6.
174. O'Leary CP, Veitch J, Durward WF, Thomas AM, Rees JH, Willison HJ. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry 1996; 61: 649-51.
175. Oldfors A. Cholera toxin B-subunit incorporation into synaptic vesicles of the neuromuscular junction of the rat. Experientia 1986; 42: 415-7.
176. O'Shannessy DJ, Willison HJ, Inuzuka T, Dobersen MJ, Quarles RH. The species distribution of nervous system antigens that react with anti-myelin-associated glycoprotein antibodies. J Neuroimmunol 1985; 9: 255-68.
177. Paparounas K, O'Hanlon GM, O'Leary CP, Rowan EG, Willison HJ. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain 1999; 122: 807-16.
178. Parry GJ, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 1988; 11: 103-7.
179. Pestronk A. Motor neuropathies, motor neuron disorders, and antiglycolipid antibodies. [Review]. Muscle Nerve 1991; 14: 927-36.
180. Pestronk A, Choksi R. Multifocal motor neuropathy: Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology 1997; 49: 1289-92.
181. Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988; 24: 73-8.
182. Pestronk A, Choksi R, Yee WC, Kornberg AJ, Lopate G, Trotter J. Serum antibodies to heparan sulfate glycosaminoglycans in Guillain-Barré syndrome and other demyelinating polyneuropathies. J Neuroimmunol 1998; 91: 204-9.
183. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225-30.
184. Plomp JJ, Molenaar PC, O'Hanlon GM, Jacobs BC, Veitch J, Daha MR, et al. Miller Fisher anti-GQ1b antibodies: α-latrotoxin-like effects on motor end plates. Ann Neurol 1999; 45: 189-99.
185. Ponsford S, Willison H, Veitch J, Morris R, Thomas PK. Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy. Muscle Nerve 2000; 23: 164-74.
186. Prendergast MM, Lastovica AJ, Moran AP. Lipopolysaccharides from Campylobacter jejuni O: 41 Strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside. Infect Immun 1998; 66: 3649-55.
187. Press R, Mata S, Lolli F, Zhu J, Andersson T, Link H. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome. J Neurol Sci 2001; 190: 41-7.
188. Quarles RH. The spectrum and pathogenesis of antibody-mediated neuropathies. [Review]. Neuroscientist 1997; 3: 195-204.
189. Quarles RH, Weiss MD. Autoantibodies associated with peripheral neuropathy. [Review]. Muscle Nerve 1999; 22: 800-22.
190. Raschetti R, Maggini M, Popoli P, Caffari B, da Cas R, Menniti-Ippolito F, et al. Gangliosides and Guillain-Barré syndrome. J Clin Epidemiol 1995; 48: 1399-405.
191. Ravindranath MH, Ravindranath RM, Morton DL, Graves MC. Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA. [Review]. J Immunol Methods 1994; 169: 257-72.
192. Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995a; 38: 809-16.
193. Rees JH, Gregson NA, Hughes RA. Anti-ganglioside antibodies in patients with Guillain-Barré syndrome and Campylobacter jejuni infection [letter]. J Infect Dis 1995b; 172: 605-6.
194. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. New Engl J Med 1995c; 333: 1374-9.
195. Richter RB. The ataxic form of polyradiculoneuritis (Landry-Guillain-Barré syndrome). J Neuropathol Exp Neurol 1962; 21: 171-84.
196. Ritz MF, Lechner-Scott J, Scott RJ, Fuhr P, Malik N, Erne B, et al. Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies. J Neuroimmunol 2000; 104: 155-63.
197. Roberts M, Willison H, Vincent A, Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet 1994; 343: 454-5.
198. Roisen FJ, Bartfeld H, Nagele R, Yorke G. Ganglioside stimulation of axonal sprouting in vitro. Science 1981; 214: 577-8.
199. Ropper AH. The CNS in Guillain-Barré syndrome [editorial]. Arch Neurol 1983; 40: 397-8.
200. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986; 43: 1150-2.
201. Ropper AH. Further regional variants of acute immune polyneuropathy. Arch Neurol 1994; 51: 671-5.
202. Ropper AH, Shahani B. Proposed mechanism of ataxia in Fisher's syndrome. Arch Neurol 1983; 40: 537-8.
203. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebskys's postulates revisited). [Review]. Immunol Today 1993; 14: 426-30.
204. Saida K, Saida T, Brown MJ, Silberberg DH. In vivo demyelination induced by intraneural injection of anti-galactocerebroside serum: A morphologic study. Am J Pathol 1979; 95: 99-116.
205. Saida T, Saida K, Dorfman SH, Silberberg DH, Sumner AJ, Manning MC, et al. Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 1979; 204: 1103-6.
206. Sakurai Y, Mannen T, Kusunoki S. Acute isolated ophthalmoplegia as a variant of Miller-Fisher syndrome [letter]. Muscle Nerve 1998; 21: 1107.
207. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992; 52: 4342-7.
208. Salloway S, Mermel LA, Seamans M, Aspinall GO, Nam Shin JE, Kurjanczyk LA, et al. Miller-Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Infect Immun 1996; 64: 2945-9.
209. Santoro M, Uncini A, Corbo M, Staugaitis SM, Thomas FP, Hays AP, et al. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol 1992; 31: 385-90.
210. Schluep M, Steck AJ. Immunostaining of motor nerve terminals by IgM M protein with activity against gangliosides GM1 and GD1b from a patient with motor neuron disease. Neurology 1988; 38: 1890-2.
211. Senda T, Sugimoto N, Horiguchi Y, Matsuda M. The enterotoxin of Clostridium perfringens type A binds to the presynaptic nerve endings in neuromuscular junctions of mouse phrenic nerve-diaphragm. Toxicon 1995; 33: 499-506.
212. Sheikh KA, Griffin JW. Variants of the Guillain Barré syndrome: Progress toward fulfilling 'Koch's postulates' [editorial]. Ann Neurol 2001; 49: 694-6.
213. Sheikh KA, Deerinck TJ, Ellisman MH, Griffin JW. The distribution of ganglioside-like moieties in peripheral nerves. Brain 1999; 122: 449-60.
214. Simons K, Ikonen E. Functional rafts in cell membranes. [Review]. Nature 1997; 387: 569-72.
215. Stangel M, Toyka KV, Gold R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. [Review]. Arch Neurol 1999; 56: 661-3.
216. Stoffel W, Bosio A. Myelin glycolipids and their functions. [Review]. Curr Opin Neurobiol 1997; 7: 654-61.
217. Sumner AJ, Saida K, Saida T, Silberberg DH, Asbury AK. Acute conduction block associated with experimental antiserum-mediated demyelination of peripheral nerve. Ann Neurol 1982; 11: 469-77.
218. Susuki K, Yuki N, Hirata K, Kuwabara S. Fine specificities of anti-LM1 IgG antibodies in Guillain-Barré syndrome. J Neurol Sci 2002; 195: 145-8.
219. Svennerholm L. Designation and schematic structure of gangliosides and allied glycosphingolipids. Prog Brain Res 1994; 101: 11-4.
220. Tagawa Y, Irie F, Hirabayashi Y, Yuki N. Cholinergic neuron-specific ganglioside GQ1b alpha a possible target molecule for serum IgM antibodies in some patients with sensory ataxia. J Neuroimmunol 1997; 75: 196-9.
221. Takano H, Yuki N. Fisher's syndrome associated with chickenpox and anti-GQlb antibody [letter]. J Neurol 1995; 242: 255-6.
222. Taki T, Ishikawa D. TLC blotting: application to microscale analysis of lipids and as a new approach to lipid-protein interaction. [Review]. Anal Biochem 1997; 251: 135-43.
223. + currents in isolated rat myelinated nerve fibers. Ann Neurol 1995; 37: 436-42.
224. Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol 1993; 33: 502-6.
225. Taylor BV, Gross L, Windebank AJ. The sensitivity and specificity of anti-GM1 antibody testing. Neurology 1996; 47: 951-5.
226. Tettamanti G, Riboni L. Gangliosides and modulation of the function of neural cells. [Review]. Adv Lipid Res 1993; 25: 235-65.
227. Thomas FP, Trojaborg W, Nagy C, Santoro M, Sadiq SA, Latov N, et al. Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier. Acta Neuropathol (Berl) 1991; 82: 378-83.
228. Thornton CA, Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. [Review]. Ann Neurol 1994; 35: 260-8.
229. Uncini A, Lugaresi A. Fisher syndrome with tetraparesis and antibody to GQ1b: Evidence for motor nerve terminal block. Muscle Nerve 1999; 22: 640-4.
230. Uncini A, Santoro M, Corbo M, Lugaresi A, Latov N. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve 1993; 16: 610-5.
231. Vanden Berg L, Hays AP, Nobile-Orazio E, Kinsella LJ, Manfredini E, Corbo M, et al. Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve 1996; 19: 637-43.
232. vander Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain- Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992; 326: 1123-9.
233. van Schaik IN, Bossuyt PM, Brand A, Vermeulen M. Diagnostic value of GM1 antibodies in motor-neuron disorders and neuropathies: A meta-analysis. Neurology 1995; 45: 1570-7.
234. Visser LH, van der Meché FG, Meulstee J, Rothbarth PP, Jacobs BC, Schmitz PI, et al. Cytomegalovirus infection and Guillain-Barré syndrome: The clinical, electrophysiologic, and prognostic features. Neurology 1996; 47: 668-73.
235. Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: Correlation and prognosis. Ann Neurol 1993; 34: 130-5.
236. Walsh FS, Cronin M, Koblar S, Doherty P, Winer J, Leon A, et al. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J Neuroimmunol 1991; 34: 43-51.
237. Wan XC, Trojanowski JQ, Gonatas JO. Cholera toxin and wheat germ agglutinin conjugates as neuroanatomical probes: Their uptake and clearance, transganglionic and retrograde transport and sensitivity. Brain Res 1982; 243: 215-24.
238. Willison HJ. Antiglycolipid antibodies in peripheral neuropathy: Fact or fiction? [Review]. J Neurol Neurosurg Psychiatry 1994; 57: 1303-7.
239. Willison HJ, Kennedy PG. Gangliosides and bacterial toxins in Guillain-Barré syndrome. [Review]. J Neuroimmunol 1993; 46: 105-12.
240. Willison HJ, O'Hanlon GM. The immunopathogenesis of Miller Fisher syndrome. [Review]. J Neuroimmunol 1999; 100: 3-12.
241. Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 1994; 50: 159-65.
242. Willison HJ, Trapp BD, Bacher J, Dalakas M, Griffin JW, Quarles RH. Demyelination induced by intraneural injection of human anti-myelin-associated glycoprotein antibodies. Muscle Nerve 1988; 11: 1169-76.
243. 2 cold agglutinins. J Neurol Neurosurg Psychiatry 1993a; 56: 1178-83.
244. Willison HJ, Veitch J, Paterson G, Kennedy PG. Miller Fisher syndrome is associated with serum antibodies to GQlb ganglioside. J Neurol Neurosurg Psychiatry 1993b; 56: 204-6.
245. Willison HJ, O'Hanlon GM, Paterson G, Veitch J, Wilson G, Roberts M, et al. A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, VI-18. J Clin Invest 1996; 97: 1155-64.
246. Willison HJ, Veitch J, Swan AV, Baumann N, Comi G, Gregson NA, et al. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 1999; 6: 71-7.
247. Willison HJ, O'Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001; 124: 1968-77.
248. Windebank AJ, Blexrud MD, Dyck PJ, Daube JR, Karnes JL. The syndrome of acute sensory neuropathy: Clinical features and electrophysiologic and pathologic changes. Neurology 1990; 40: 584-91.
249. Winer JB. Bickerstaff's encephalitis and the Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2001; 71: 433-5.
250. Wirguin I, Briani C, Suturkova-Milosevic L, Fisher T, Della-Latta P, Chalif P, et al. Induction of anti-GM1 ganglioside antibodies by Campylobacter jejuni lipopolysaccharides. J Neuroimmunol 1997; 78: 138-42.
251. Witebsky E. Historical roots of present concepts of immunopathology. In: Grabar P, Miescher P, editors. 1st International Symposium on Immunopathology. Basel: Benno Schwabe; 1959. p. 1.
252. Wu G, Ledeen RW. Gangliosides as modulators of neuronal calcium. Proc Brain Res 1994; 101: 101-12.
253. Yako K, Kusunoki S, Kanazawa I. Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barré syndrome. J Neurol Sci 1999; 168: 85-9.
254. Yamawaki M, Vasquez A, Ben Younes A, Yoshino H, Kanda T, Ariga T, et al. Sensitization of Lewis rats with sulfoglucuronosyl paragloboside: Electrophysiological and immunological studies of an animal model of peripheral neuropathy. J Neurosci Res 1996; 44: 58-65.
255. Yu RK, Ariga T. The role of glycosphingolipids in neurological disorders: Mechanisms of immune action. [Review]. Ann NY Acad Sci 1998; 845: 285-306.
256. Yuki N. Acute paresis of extraocular muscles associated with IgG anti-GQlb antibody. Ann Neurol 1996; 39: 668-72.
257. Yuki N, Tagawa Y. Acute cytomegalovirus infection and IgM anti-GM2 antibody. J Neurol Sci 1998; 154: 14-7.
258. Yuki N, Tsujino Y. Familial Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis [letter]. J Pediatr 1995; 126: 162.
259. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990; 40: 1900-2.
260. Yuki N, Sato S, Miyatake T, Sugiyama K, Katagiri T, Sasaki H. Motoneuron-disease-like disorder after ganglioside therapy [letter]. Lancet 1991; 337: 1109-10.
261. Yuki N, Miyatake T, Ichihashi Y, Sato S, Katagiri T. IgM anti-(GalNAc beta1-4 Gal [3-2beta NeuAc] beta1-) antibody-mediated cytotoxicity in a patient with amyotrophic lateral sclerosis-like disorder [letter]. Muscle Nerve 1992a; 15: 1371-3.
262. Yuki N, Miyatani N, Sato S, Hirabayashi Y, Yamazaki M, Yoshimura N, et al. Acute relapsing sensory neuropathy associated with IgM antibody against B-series gangliosides containing a GalNAc beta1-4 Gal(3-2alpha?NeuAc 8-2alpha NeuAc) beta1 configuration. Neurology 1992b; 42: 686-9.
263. Yuki N, Yoshino H, Sato S, Shinozawa K, Miyatake T. Severe acute axonal form of Guillain-Barré syndrome associated with IgG anti-GD1a antibodies. Muscle Nerve 1992c; 15: 899-903.
264. Yuki N, Sato S, Tsuji S, Hozumi I, Miyatake T. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 1993a; 118: 83-7.
265. Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology 1993b; 43: 414-7.
266. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993c; 178: 1771-5.
267. Yuki N, Yamada M, Sato S, Ohama E, Kawase Y, Ikuta F, et al. Association of IgG anti-GD1a antibody with severe Guillain-Barré syndrome. Muscle Nerve 1993d; 16: 642-7.
268. Yuki N, Taki T, Takahashi M, Saito K, Tai T, Miyatake T, et al. Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope. Infect Immun 1994a; 62: 2101-3.
269. Yuki N, Taki T, Takahashi M, Saito K, Yoshino H, Tai T, et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994b; 36: 791-3.
270. Yuki N, Handa S, Tai T, Takahashi M, Saito K, Tsujino Y, et al. Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain-Barré syndrome. J Neurol Sci 1995; 130: 112-6.
271. Yuki N, Tagawa Y, Handa S. Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1996a; 70: 1-6.
272. Yuki N, Taki T, Handa S. Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J Neuroimmunol 1996b; 71: 155-61.
273. Yuki N, Tagawa Y, Irie F, Hirabayashi Y, Handa S. Close association of Guillain-Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1alpha. J Neuroimmunol 1997a; 74: 30-4.
274. Yuki N, Takahashi M, Tagawa Y, Kashiwase K, Tadokoro K, Saito K. Association of Campylobacter jejuni serotype with antiganglioside antibody in Guillain-Barré syndrome and Fisher's syndrome. Ann Neurol 1997b; 42: 28-33.
275. Yuki N, Yamada M, Tagawa Y, Takahashi H, Handa S. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J Neurol Sci 1997c; 149: 127-30.
276. Yuki N, Yamamoto T, Hirata K. Correlation between cytomegalovirus infection and IgM anti-MAG/SGPG antibody-associated neuropathy. Ann Neurol 1998; 44: 408-10.
277. Yuki N, Ho TW, Tagawa Y, Koga M, Li CY, Hirata K, et al. Autoantibodies to GM1b and GalNAc-GD1a: Relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China. J Neurol Sci 1999a; 164: 134-8.
278. Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci 1999b; 168: 121-6.
279. Yuki N, Ang CW, Koga M, Jacobs BC, van Doorn PA, Hirata K, et al. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 2000a; 47: 314-21.
280. Yuki N, Susuki K, Hirata K. Ataxic Guillain-Barré syndrome with anti-GQ1b antibody: Relation to Miller Fisher syndrome. Neurology 2000b; 54: 1851-3.
281. Yuki N, Susuki K, Hirata K. Ataxic form of Guillain-Barré syndrome associated with anti-GD1b IgG antibody [letter]. J Neurol Neurosurg Psychiatry 2000c; 69: 136-7.
282. Yuki N, Odaka M, Hirata K. Acute ophthalmoparesis (without ataxia) associated with anti-GQ1b IgG antibody: Clinical features. Ophthalmology 2001a; 108: 196-200.
283. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001b; 49: 712-20.
284. Zielasek J, Ritter G, Magi S, Hartung HP, Toyka KV. A comparative trial of anti-glycoconjugate antibody assays: IgM antibodies to GM1. J Neurol 1994; 241: 475-80.